Polymer-directed enzyme prodrug therapy

Drug News and Perspectives

Volumn 13, Issue 8, 2000, Pages 477-480

  Cassidy, J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYSTEINE PROTEINASE; CYTOTOXIC AGENT; DOXORUBICIN DERIVATIVE; DRUG CARRIER; ENZYME; MELPHALAN; N (2 HYDROXYPROPYL)METHACRYLAMIDE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER DOXORUBICIN; PEPTIDE; PK1; POLYMER; PRODRUG; UNCLASSIFIED DRUG;

CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CROSS LINKING; DRUG ACTIVATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; PHASE 1 CLINICAL TRIAL; REVIEW;

EID: 0034511833     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Structures and properties of pharmacologically active polymers
2. Tumouritropic and lymphotropic principles of macromolecular drugs
3. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model
4. Pharmacokinetics of polymer-bound adriamycin
5. HPMA coploymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line
6. Phase 1 clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates